Editorial: safety in numbers-cycling of biologics does not increase risk of adverse outcomes.
作者信息
Faye Adam S, Axelrad Jordan E
机构信息
Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, New York City, USA.
出版信息
Aliment Pharmacol Ther. 2022 Jun;55(11):1459-1460. doi: 10.1111/apt.16936.
Abstract
摘要
相似文献
1
Editorial: safety in numbers-cycling of biologics does not increase risk of adverse outcomes.社论：人多势众——生物制品的循环使用不会增加不良后果的风险。
Aliment Pharmacol Ther. 2022 Jun;55(11):1459-1460. doi: 10.1111/apt.16936.
2
The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.新型生物制剂治疗类风湿关节炎的疗效与耐受性：当前最佳证据
Curr Opin Rheumatol. 2007 May;19(3):308-13. doi: 10.1097/01.bor.0000265447.48722.04.
3
Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events.治疗类风湿关节炎的生物制剂的安全性：不良事件自发报告分析。
Clin Rheumatol. 2013 Aug;32(8):1207-14. doi: 10.1007/s10067-013-2256-9. Epub 2013 Apr 21.
4
Comparative overview of safety of the biologics in rheumatoid arthritis.类风湿关节炎生物制剂安全性的比较概述
J Rheumatol Suppl. 2009 Jun;82:25-32. doi: 10.3899/jrheum.090128.
5
Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis.生物制剂在老年类风湿关节炎患者中的安全性
J Rheumatol. 2016 Nov;43(11):1984-1988. doi: 10.3899/jrheum.160012. Epub 2016 Sep 1.
6
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.生物制剂治疗的类风湿关节炎患者的严重感染：来自英国风湿病学会生物制剂登记处类风湿关节炎的结果。
Ann Rheum Dis. 2018 Jun;77(6):905-910. doi: 10.1136/annrheumdis-2017-212825. Epub 2018 Mar 28.
7
[Discussion meeting on treatment of rheumatoid arthritis with biologics and their side effects].[生物制剂治疗类风湿关节炎及其副作用讨论会]
Nihon Naika Gakkai Zasshi. 2011 Oct 10;100(10):2998-3017. doi: 10.2169/naika.100.2998.
8
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.在对肿瘤坏死因子抑制剂反应不足的活动性类风湿关节炎患者中，非肿瘤坏死因子生物制剂和 Janus 激酶抑制剂的比较有效性和安全性：一项随机对照试验的贝叶斯网络荟萃分析
J Clin Pharm Ther. 2021 Aug;46(4):984-992. doi: 10.1111/jcpt.13380. Epub 2021 Feb 18.
9
Treatment of rheumatoid arthritis with biologics.
Schweiz Med Wochenschr Suppl. 1996;80:22S-23S.
10
Use of biologics in rheumatoid arthritis: where are we going?生物制剂在类风湿关节炎中的应用：我们将何去何从？
Am J Health Syst Pharm. 2006 Sep 15;63(18 Suppl 4):S19-41. doi: 10.2146/ajhp060365.
本文引用的文献
1
Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre.炎症性肠病序贯生物治疗的安全性：来自三级转诊中心的结果。
Aliment Pharmacol Ther. 2022 Jul;56(2):271-281. doi: 10.1111/apt.16928. Epub 2022 Apr 20.
2
Sarcopenia as a Risk Prediction Tool in Inflammatory Bowel Disease.肌肉减少症作为炎症性肠病的风险预测工具
Inflamm Bowel Dis. 2022 Dec 1;28(12):1932-1933. doi: 10.1093/ibd/izac069.
3
Safety and Efficacy of Anti-TNF Therapy in Older Adults With Ulcerative Colitis: A New Path Forward.抗TNF治疗在老年溃疡性结肠炎患者中的安全性和有效性：一条新的前进道路。
Gastroenterology. 2022 May;162(6):1762-1764. doi: 10.1053/j.gastro.2021.12.003. Epub 2021 Dec 2.
4
Frailty in inflammatory bowel diseases: an emerging concept.炎症性肠病中的衰弱：一个新兴概念。
Therap Adv Gastroenterol. 2021 Sep 24;14:17562848211025474. doi: 10.1177/17562848211025474. eCollection 2021.
5
Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort.美国炎症性肠病队列中皮质类固醇的使用及并发症
PLoS One. 2016 Jun 23;11(6):e0158017. doi: 10.1371/journal.pone.0158017. eCollection 2016.
6
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.炎症性肠病与癌症：炎症、免疫抑制及癌症治疗的作用
World J Gastroenterol. 2016 May 28;22(20):4794-801. doi: 10.3748/wjg.v22.i20.4794.
7
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.生物疗法与炎症性肠病患者感染和恶性肿瘤风险：系统评价和网络荟萃分析。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14.
8
Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.硫唑嘌呤使用与炎症性肠病患者非黑色素瘤皮肤癌的关联：一项荟萃分析。
Am J Gastroenterol. 2014 Feb;109(2):163-9. doi: 10.1038/ajg.2013.451. Epub 2014 Jan 14.
Zotero 插件